LOG IN
SIGN UP
MARKET
PODD
PODD
Insulet Corp
NASDAQ
Real-time Quotes | Nasdaq Last Sale
229.06
+7.41
+3.34%
After Hours: 229.06 0 0.00% 16:08 05/26 EDT
OPEN
221.65
PREV CLOSE
221.65
HIGH
232.15
LOW
217.61
VOLUME
914.97K
TURNOVER
0
52 WEEK HIGH
324.81
52 WEEK LOW
181.00
MARKET CAP
15.88B
P/E (TTM)
377.80
1D
5D
1M
3M
1Y
5Y
Looking Into Insulet's Return On Capital Employed
According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4.
Benzinga · 10h ago
Why These 10 Stocks Are Trending on Tuesday
In this article, we will discuss some of the notable stocks trending today. To take a look at some more stocks that are in the news, go to Why These 5 Stocks Are Trending on Tuesday. Following a short respite, investors returned to selling shares on Tuesda...
Insider Monkey · 2d ago
How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space
Dexcom stock tumbled Tuesday on rumors that it's in talks to acquire insulin pump-maker Insulet. Insulet stock, on the other hand, popped.
Investor's Business Daily · 2d ago
Hot Stocks: UBER drops on cautious comment; INMB regulatory setback; CTRN rises on earnings; DXCM falls
Uber (NYSE:UBER) was among the standout decliners on an overall weak day for the market, dropping in Tuesday's midday trading following a cautious analyst comment. INmune Bio (INMB) also suffered
Seekingalpha · 2d ago
Allarity, Better Therapeutics top healthcare gainers; INmune Bio, Liquidia lead losers' pack
Gainers: Allarity Therapeutics (ALLR) +13%. Better Therapeutics (BTTX) +19%. GeoVax Labs (GOVX) +10%. Insulet (PODD) +7%. MDxHealth (MDXH) +5%. Losers: INmune Bio (INMB) -29%. Liquidia (LQDA) -21%. TherapeuticsMD (TXMD) -19%. Aethlon Medical (AEMD) -14%. S...
Seekingalpha · 2d ago
CANG,CELZ and BTTX among pre market gainers
Better Therapeutics (BTTX) +12%. Insulet Corporation (PODD) +11% DexCom - Insulet buyout deal unlikely, Bank of America says. Cango (CANG) +10%. Roivant Sciences (ROIV) +10% gets FDA approval for plaque psoriasis therapy Vtama cream.
Seekingalpha · 2d ago
Insulet's stock is up on Bloomberg report that it may be acquired by Dexcom
Shares of Insulet Corp. gained 9.9% in premarket trading on Tuesday, the day after Bloomberg reported that the company is in talks to be acquired by Dexcom Inc. , citing anonymous sources. Dexcom's stock was down 7.1% before the market opened on Tuesday. A...
marketwatch.com · 2d ago
Market Chatter: DexCom In Talks To Buy Insulet, Sources Say
MT Newswires · 2d ago
No Data
Learn about the latest financial forecast of PODD. Analyze the recent business situations of Insulet Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 17 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
47.06%Strong Buy
23.53%Buy
23.53%Hold
5.88%Under-perform
0.00%Sell
Analyst Price Target
The average PODD stock price target is 277.93 with a high estimate of 345.00 and a low estimate of 230.00.
Current 229.06
EPS
Actual
Estimate
-0.19-0.010.170.35
Institutional Holdings
Institutions: 634
Institutional Holdings: 81.00M
% Owned: 116.82%
Shares Outstanding: 69.34M
TypeInstitutionsShares
Increased
181
6.81M
New
62
984.24K
Decreased
154
5.96M
Sold Out
54
757.60K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+0.54%
Healthcare Equipment & Supplies
+0.56%
Key Executives
Non-Executive Chairman/Independent Director
Timothy Scannell
President/Chief Executive Officer/Director
Shacey Petrovic
Chief Financial Officer/Executive Vice President/Treasurer
Wayde McMillan
Chief Operating Officer/Executive Vice President
Charles Alpuche
Chief Human Resource Officer/Senior Vice President
Dan Manea
Executive Vice President
Eric Benjamin
Executive Vice President
Bret Christensen
Senior Vice President/General Counsel
John Kapples
Senior Vice President
Michael Spears
Director
Elizabeth Weatherman
Independent Director
Luciana Borio
Independent Director
Wayne Frederick
Independent Director
James Hollingshead
Independent Director
Jessica Hopfield
Independent Director
Michael Minogue
Independent Director
Corinne Nevinny
No Data
No Data
About PODD
Insulet Corporation is primarily engaged in the development, manufacture and sale of its proprietary Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. It can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.
Webull offers kinds of Insulet Corporation stock information, including NASDAQ:PODD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PODD stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading PODD stock methods without spending real money on the virtual paper trading platform.